📣 VC round data is live. Check it out!

Aroa Biosurgery Valuation Multiples

Discover revenue and EBITDA valuation multiples for Aroa Biosurgery and similar public comparables like JETEMA Co., Guerbet, Viromed Medical, Quanterix and more.

Aroa Biosurgery Overview

About Aroa Biosurgery

Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.


Founded

2007

HQ

United States

Employees

251

Website

aroa.com

Financials (LTM)

Revenue: $63M
EBITDA: $7M

EV

$151M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Aroa Biosurgery Financials

Aroa Biosurgery reported last 12-month revenue of $63M and EBITDA of $7M.

In the same LTM period, Aroa Biosurgery generated $54M in gross profit, $7M in EBITDA, and $2M in net income.

Revenue (LTM)


Aroa Biosurgery P&L

In the most recent fiscal year, Aroa Biosurgery reported revenue of $55M and EBITDA of $3M.

Aroa Biosurgery is unprofitable as of last fiscal year, with gross margin of 86%, EBITDA margin of 5%, and net margin of (4%).

See analyst estimates for Aroa Biosurgery
LTMLast FY202320242025202620272028
Revenue$63M$55M$45M$53M$60M
Gross Profit$54M$48M$38M$45M$52M
Gross Margin86%86%85%86%86%
EBITDA$7M$3M($2M)$643K$6M
EBITDA Margin11%5%(4%)1%9%
EBIT Margin6%(1%)(22%)(14%)2%
Net Profit$2M($2M)($5M)($4M)$955K
Net Margin4%(4%)(12%)(7%)2%

Financial data powered by Morningstar, Inc.

Aroa Biosurgery Stock Performance

Aroa Biosurgery has current market cap of $161M, and enterprise value of $151M.

Market Cap Evolution


Aroa Biosurgery's stock price is $0.46.

Aroa Biosurgery share price increased by 3.4% in the last 30 days, and by 28.2% in the last year.

Aroa Biosurgery has an EPS (earnings per share) of $-0.01.

See more trading valuation data for Aroa Biosurgery
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$151M$161M5.4%3.4%-3.4%28.2%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Aroa Biosurgery Valuation Multiples

Aroa Biosurgery trades at 2.4x EV/Revenue multiple, and 21.5x EV/EBITDA.

See NTM and 2027E valuation multiples for Aroa Biosurgery

EV / Revenue (LTM)


Aroa Biosurgery Financial Valuation Multiples

As of May 7, 2026, Aroa Biosurgery has market cap of $161M and EV of $151M.

Aroa Biosurgery has a P/E ratio of 67.9x.

LTMLast FY202320242025202620272028
EV/Revenue2.4x2.7x3.4x2.8x2.5x
EV/EBITDA21.5x60.0x(84.7x)234.4x27.0x
EV/EBIT38.2x(195.3x)(15.4x)(21.0x)112.9x
EV/Gross Profit2.8x3.2x3.9x3.3x2.9x
P/E67.9x(70.7x)(30.2x)(44.4x)168.8x
EV/FCF27.8x(47.9x)(16.7x)(27.6x)50.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Aroa Biosurgery Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Aroa Biosurgery Margins & Growth Rates

Aroa Biosurgery grew revenue by 12% and EBITDA by 170% in the last fiscal year.

In the most recent fiscal year, Aroa Biosurgery reported gross margin of 86%, EBITDA margin of 5%, and net margin of (4%).

See estimated margins and future growth rates for Aroa Biosurgery

Aroa Biosurgery Margins

Last FY202420252026202720282029
Gross Margin86%86%86%86%
EBITDA Margin5%1%9%12%
EBIT Margin(1%)(14%)2%8%
Net Margin(4%)(7%)2%6%
FCF Margin(6%)(10%)5%9%

Aroa Biosurgery Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth12%18%14%14%
Gross Profit Growth12%19%14%14%
EBITDA Growth170%(136%)766%51%
EBIT Growth(584%)(27%)(119%)297%
Net Profit Growth(192%)(32%)(126%)327%
FCF Growth(269%)(40%)(154%)105%

Data powered by FactSet, Inc. and Morningstar, Inc.

Aroa Biosurgery Operational KPIs

Aroa Biosurgery's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.2M for the same period.

Aroa Biosurgery's Rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Aroa Biosurgery's Rule of X is 46% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Aroa Biosurgery
LTMLast FY202320242025202620272028
Rule of 4025%26%———
Bessemer Rule of X47%46%———
Revenue per Employee—$0.2M———
Opex per Employee—$0.2M———
S&M Expenses to Revenue—79%86%81%73%
R&D Expenses to Revenue9%11%14%12%9%
Opex to Revenue—96%107%99%88%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Aroa Biosurgery Competitors

Aroa Biosurgery competitors include JETEMA Co., Guerbet, Viromed Medical, Quanterix, Hyperfine, Sisram Medical, Neuronetics, EKF Diagnostics, BICO Group and Pro-Dex.

Most Aroa Biosurgery public comparables operate across Medical Devices, BioTech, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
JETEMA Co.4.6x—30.7x—
Guerbet0.5x0.6x6.0x5.1x
Viromed Medical—5.4x(666.9x)39.4x
Quanterix0.5x0.5x(0.8x)(2.0x)
Hyperfine9.8x8.4x(3.7x)(3.9x)
Sisram Medical0.4x0.4x2.9x3.7x
Neuronetics1.4x1.4x(7.6x)(11.7x)
EKF Diagnostics1.9x1.9x7.8x7.8x

This data is available for Pro users. Sign up to see all Aroa Biosurgery competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Aroa Biosurgery

When was Aroa Biosurgery founded?Aroa Biosurgery was founded in 2007.
Where is Aroa Biosurgery headquartered?Aroa Biosurgery is headquartered in United States.
How many employees does Aroa Biosurgery have?As of today, Aroa Biosurgery has over 251 employees.
Is Aroa Biosurgery publicly listed?Yes, Aroa Biosurgery is a public company listed on Australian Securities Exchange.
What is the stock symbol of Aroa Biosurgery?Aroa Biosurgery trades under ARX ticker.
When did Aroa Biosurgery go public?Aroa Biosurgery went public in 2020.
Who are competitors of Aroa Biosurgery?Aroa Biosurgery main competitors include JETEMA Co., Guerbet, Viromed Medical, Quanterix, Hyperfine, Sisram Medical, Neuronetics, EKF Diagnostics, BICO Group, Pro-Dex.
What is the current market cap of Aroa Biosurgery?Aroa Biosurgery's current market cap is $161M.
What is the current revenue of Aroa Biosurgery?Aroa Biosurgery's last 12 months revenue is $63M.
What is the current revenue growth of Aroa Biosurgery?Aroa Biosurgery revenue growth (NTM/LTM) is 14%.
What is the current EV/Revenue multiple of Aroa Biosurgery?Current revenue multiple of Aroa Biosurgery is 2.4x.
Is Aroa Biosurgery profitable?Yes, Aroa Biosurgery is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Aroa Biosurgery?Aroa Biosurgery's last 12 months EBITDA is $7M.
What is Aroa Biosurgery's EBITDA margin?Aroa Biosurgery's last 12 months EBITDA margin is 11%.
What is the current EV/EBITDA multiple of Aroa Biosurgery?Current EBITDA multiple of Aroa Biosurgery is 21.5x.
What is the current FCF of Aroa Biosurgery?Aroa Biosurgery's last 12 months FCF is $5M.
What is Aroa Biosurgery's FCF margin?Aroa Biosurgery's last 12 months FCF margin is 9%.
What is the current EV/FCF multiple of Aroa Biosurgery?Current FCF multiple of Aroa Biosurgery is 27.8x.
How many companies Aroa Biosurgery has acquired to date?Aroa Biosurgery hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Aroa Biosurgery has invested to date?Aroa Biosurgery hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Aroa Biosurgery

Lists including Aroa Biosurgery

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial